Discgenics Receives "Notice of Issuance" on its First U.S. Patent Application

SALT LAKE CITY, July 25, 2012 /PRNewswire/ --  Discgenics, Inc. (Discgenics) announced today the receipt of a "Notice of Issuance" from the United States Patent and Trademark Office (USPTO) on it first patent, "Compositions of Adult Disc Stem Cells and Methods for the Treatment of Degenerative Disc Disease".

Discgenics' CEO, Flagg Flanagan said, "We are excited to have obtained our first patent that provides Discgenics with coverage on our proprietary culture system that includes a resulting composition comprising a disc stem cell population from a nucleus pulposus source that forms Discospheres™ when grown following the Discgenics culture system method." Discgenics has a series of additional patent applications that include more recent scientific discoveries, and will be expanded to cover the specific devices that will utilize the Discosphere technology.

About Discgenics, Inc.

Discgenics is a privately funded spinal therapeutics company that is utilizing adult human disc stem cells within a tissue engineering approach to treat patients debilitated by Degenerative Disc Disease. News and other information on the company are available at: http://www.discgenics.com.

Media Contact: Flagg Flanagan
Chief Executive Officer
801-410-0703
[email protected]

SOURCE Discgenics, Inc.

Launch Readiness

Optimize cross-functional collaboration and engage with key stakeholders for the successful launch of a product

Join the Launch Readiness for Medical Affairs & Communications Teams Summit to learn best practices in taking a structured approach to enhance medical affairs activities surrounding a launch and increase knowledge and communication with thought leaders.